print   Bookmark and Share  |  RSS  |  A  A  A

Event Calendar & Registration

Event Registration


Back to Events
PRESENTATIONS - Debates and Didactics in Hematology & Oncology
Description: Download slides
Date: Saturday, July 27, 2013
Details:

Conference Presentations


Download Agenda

Thursday, July 25, 2013/Gastrointestinal Cancers, Myeloma, and Glioblastoma Sessions

Debate ONE – Peritoneal Mets: Chemotherapy or Surgery?
Chemotherapy: John Kauh, MD
Surgery: Charles A. Staley, MD

Adjunct Therapy for Stage II Colon Cancer
John Kauh, MD

Management of Stage IV Colorectal Cancer: New Treatment Options
Bassel F. El-Rayes, MD

Debate TWO – Early-Stage GEJ Preoperative Therapy: Chemotherapy/XRT vs Chemotherapy Alone
Chemotherapy/XRT: Jerome C. Landry, MD
Chemotherapy Alone: Bassel F. El-Rayes, MD

Management of Borderline Resectable Pancreatic Cancer
David A. Kooby, MD

Limb-Sparing Surgery for Sarcoma
David K. Monson, MD

New Treatment Options for Relapsed Multiple Myeloma
Sagar Lonial, MD

How I Approach Newly Diagnosed Multiple Myeloma
Kenneth C. Anderson, MD

Debate THREE – All Patients With Waldenström’s Macroglobulinemia Should Receive Bortezomib Based Induction
Pro: Jonathan L. Kaufman, MD
Con: Leonard T. Heffner, Jr., MD

How I Diagnose and Manage Amyloid
Jonathan L. Kaufman, MD

Debate FOUR – Surgery or Radio Surgery for Brain Mets
Pro: Costas G. Hadjipanayis, MD, PhD
Con: Ian Crocker, MD

Detection and Management of Pseudoprogression in Glioblastoma
Jeffrey J. Olson, MD

 

Friday, July 26, 2013/Breast Cancers, Leukemias, and Myeloproliferative Disorders Sessions

Debate FIVE – Imatinib Is No Longer the Standard Therapy for CML
Pro: H. Jean Khoury, MD
Con: Hagop M. Kantarjian, MD

How to Diagnose and Workup Myeloproliferative Neoplasms
Elliott F. Winton, MD

What is the Role of Allotransplant for Older Patients?
Amelia A. Langston, MD

Debate SIX – Rituximab Is Frontline Therapy for ITP
Pro: Morgan M. McLemore, MD
Con: Jacques Galipeau, MD

New Treatment Options for Relapsed and Newly Diagnosed CLL
Susan M. O’Brien, MD

Debate SEVEN– Hormonal Therapy With or Without mTOR Inhibition in First-line ER+ MBC: A Debate
Pro: Amelia Zelnak, MD
Con: Ruth M. O’Regan, MD

Novel Therapies for Trastuzumab-Resistant Breast Cancer
Ruth M. O’Regan, MD

Updates in Refractory Breast Cancer
Amelia Zelnak, MD

Debate EIGHT – Chemotherapy vs Hormonal Therapy for Stage Ia-Ib Triple-Positive Breast Cancer
Chemotherapy: Ruth M. O’Regan, MD
Hormonal: Amelia Zelnak, MD

Molecular Profiling in DCIS Mylin Torres, MD

Debate NINE – All Patients Should Receive New Oral Anticoagulant Prophylaxis for VTE: A Debate
Pro: Christine L. Kempton, MD
Con: Morgan M. McLemore, MD

Diagnosis, Workup, and Management of MDS
Martha L. Arellano, MD

 

Saturday, July 27, 2013/Lung, Head and Neck, and Lymphomas Sessions

Debate TEN – PET Scan Is a Standard Test for Lung Cancer
Pro: Suresh Ramalingam, MD
Con: Walter J. Curran, Jr., MD

Promising Novel Agents in NSCLC
Fadlo R. Khuri, MD

Optimal Local Therapy for Early-Stage Lung Cancer
Walter J. Curran, Jr., MD

Debate ELEVEN – Should EGFR TKIs Be First-line Therapy for NSCLC?
Pro: Suresh Ramalingam, MD
Con: Taofeek K. Owonikoko, MD, PhD

HPV-Positive Head and Neck Cancer: What’s New
Dong M. Shin, MD

Debate TWELVE – Is Induction Chemotherapy in Head and Neck Cancer Dead?
Pro: Jonathan J. Beitler, MD, MBA
Con: Fadlo R. Khuri, MD

Debate THIRTEEN – Imaging Has No Role in Post-Therapy Surveillance of Lymphoma
Pro: James O. Armitage, MD
Con: Christopher R. Flowers, MD

What Is the Best Strategy for Double-Hit Lymphoma?
Amelia A. Langston, MD

Viral-Related Lymphomas: New Approaches and Agents
Mary Jo Lechowicz, MD

Debate FOURTEEN – Does Allogeneic Transplantation Have a Role in Relapsed Hodgkin Disease?
Yes: Edmund K. Waller, MD, PhD
No: Jonathan L. Kaufman, MD

Debate FIFTEEN – Early vs Delayed Use of Bevacizumab for High-Grade Gliomas
Early: Alfredo D. Voloschin, MD
Delayed: Jeffrey J. Olson, MD

Management of Thyroid and Neuroendocrine Tumors
Taofeek K. Owonikoko, MD, PhD

 

Sunday, July 28, 2013/Genitourinary, Melanoma, and Ovarian Cancer Sessions

Debate SIXTEEN – Neoadjuvant vs Adjuvant Therapy in Bladder Cancer
Neoadjuvant: Bradley Carthon, MD, PhD
Adjuvant: Viraj Master, MD, PhD

New Treatment Options for Hormone-Resistant Prostate Cancer
Bradley Carthon, MD, PhD

Treatment of RCC
Michael B. Atkins, MD

Debate SEVENTEEN – Immunotherapy vs Targeted Therapy for Metastatic Melanoma: Which Is First?
Immunotherapy: Michael B. Atkins, MD
Targeted: David H. Lawson, MD

New Approaches for Relapsed Melanoma
Michael B. Atkins, MD

New Treatment Options for Relapsed Ovarian Cancer
Ira R. Horowitz, MD

Contact:
 
Additional Information